# ZENAS BIOPHARMA INC (ZBIO)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ZBIO/

- Reporting holders: 3
- Reported value: $8.4K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $8.0K | 297 | 0.0% | 7 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $324 | 12 | 0.0% | 2 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $27 | 1 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 3 | $8.4K |
| Q2 2026 | 149 | $1.6B |
| Q1 2026 | 141 | $1.2B |
| Q4 2025 | 127 | $1.6B |
| Q3 2025 | 81 | $774.9M |
| Q2 2025 | 73 | $330.0M |
| Q1 2025 | 67 | $256.7M |
| Q4 2024 | 65 | $259.8M |
| Q3 2024 | 44 | $418.5M |
| Q1 2020 | 1 | $9.0K |
| Q4 2019 | 5 | $441.0K |
| Q3 2019 | 5 | $596.0K |